John McCamant
BIOTECH
Editor
Medical Technology Stock Letter
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
Speaker Schedule
Profiting from the Next Wave in Tech & Biotech*
August 16, 2020, 3:30 pm - 5:30 pm
Focus: TECHNOLOGY
MASTER CLASS